Global Real World Evidence (RWE) Oncology Market size is valued at USD 772.5 Mn in 2024 and is predicted to reach USD 2,373.9 Mn by the year 2034 at a 12.1% CAGR during the forecast period for 2025-2034.
Real-world evidence (RWE) is the term used in the healthcare industry to describe data and information obtained from patient experiences, real-world clinical practice, and other non-clinical study situations. For oncologists to understand how cancer medications function in actual patient populations outside the controlled setting of clinical trials, real-world evidence (RWE) is essential. Advances in data analytics, machine learning, and artificial intelligence have made it easier to glean insightful information from vast volumes of actual patient data.
The globally rising incidence and prevalence of cancer, the need for real-world evidence in drug development, the growing emphasis on value-based healthcare, regulatory support for real-world evidence (RWE) in healthcare decision-making, and advancements in data analytics and artificial intelligence technologies are the primary factors driving the market for RWE in oncology. The real-world evidence (RWE) oncology market is evolving due to the introduction of cloud-based RWE platforms, the integration of genetic and molecular data, the shift towards patient-centric healthcare models, and the adoption of real-time data gathering and analysis.
Furthermore, particularly in developed economies with sophisticated healthcare infrastructures, integration with precision medicine projects and the development of analytics solutions driven by artificial intelligence (AI) are receiving considerable attention. Moreover, there are many opportunities for significant growth in the real-world evidence (RWE) oncology market. For industry participants seeking to tap into new client bases, expansion into emerging markets presents essential opportunities.
Some of the Major Key Players in the Real World Evidence (RWE) Oncology Market are:
The Real-World Evidence (RWE) Oncology market is segmented by component, application, and end-user. Based on component, the market is segmented into consulting services and datasets (disparate datasets {pharmacy data, EMR/EHR/clinical data, cancer registries, claims & billing data, others}, Integrated Datasets). By application, the market is segmented into drug development and approvals, post-market surveillance, market access and reimbursement/coverage decisions, medical device development and approvals, and others. By end-user, the market is segmented into pharmaceutical, biotechnology, and medical device companies, healthcare providers, healthcare payers, and others.
The datasets category is expected to hold a major global market share in 2021 mainly due to the growing need for thorough cancer data from all sources within the healthcare system, including integrated and disparate datasets (such as EMR/EHR/clinical data, claims & billing data, pharmacy data, and cancer registries]. Their extensive coverage, dependable data, and widespread use in various healthcare applications make them essential for pharmaceutical research, regulatory filings, and informed healthcare decision-making. There are datasets in a secondary format that are used for retrospective research to produce empirical evidence. This empirical data offers valuable insights into unmet requirements as well as the financial and clinical effects on patients and healthcare systems. Clinical studies are more efficient and less expensive, and the results are based on significantly larger data samples.
The market was dominated by the drug development and approvals segment, which was fueled by rising pharmaceutical investment in oncology research and the regulatory adoption of real-world evidence (RWE) in drug approval procedures. Pharmaceutical companies, healthcare providers, and payers can manage their operations more effectively and expedite the medication research and approval process by utilising real-world evidence (RWE) in oncology. This promotes the expansion of the real-world evidence (RWE) oncology market. Additionally, governments are implementing various programs to encourage the application of real-world evidence (RWE) in oncology for the creation and approval of medical devices.
The North American Real World Evidence (RWE) Oncology market is expected to hold the highest market share in revenue in the near future due to the region’s sophisticated healthcare system, robust RWE regulations, established pharmaceutical sector, favourable reimbursement practices, and abundance of well-established RWE solution suppliers. Furthermore, the real-world evidence (RWE) oncology market is greatly influenced by high cancer incidence rates and sophisticated data analytics skills. In addition, the Asia Pacific is projected to grow rapidly in the global Real World Evidence (RWE) Oncology market due to the increasing number of government programs encouraging the use of RWE oncology studies and the presence of several contract research and production firms in countries like China and India. The real-world evidence (RWE) in the oncology industry is expected to increase due to the rising demand for improved healthcare services.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 772.5 Mn |
|
Revenue Forecast In 2034 |
USD 2,373.9 Mn |
|
Growth Rate CAGR |
CAGR of 12.1% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Form, Product, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
IQVIA Holdings Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., Veracyte Inc., Flatiron Health Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Anthem Inc., Clinigen Group pic, PerkinElmer Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, and Tempus Labs Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RWE Oncology Market Snapshot
Chapter 4. Global RWE Oncology Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global RWE Oncology Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on RWE Oncology Market Industry Trends
Chapter 5. RWE Oncology Market Segmentation 1: By Component, Estimates & Trend Analysis
5.1. Market Share by Component, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Component:
5.2.1. Datasets
5.2.1.1. Disparate Datasets
5.2.1.2. EMR/EHR/Clinical Data
5.2.1.3. Claims & Billing Data
5.2.1.4. Pharmacy Data
5.2.1.5. Cancer Registries
5.2.1.6. Other Disparate Datasets
5.2.1.7. Integrated Datasets
5.2.2. Consulting Services
Chapter 6. RWE Oncology Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Drug Development & Approvals
6.2.2. Market Access & Reimbursement/Coverage Decisions
6.2.3. Medical Device Development & Approvals
6.2.4. Post-market Surveillance
6.2.5. Other Applications
Chapter 7. RWE Oncology Market Segmentation 3: By End User, Estimates & Trend Analysis
7.1. Market Share by End User, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
7.2.1. Pharmaceutical, Biotechnology, and Medical Device Companies
7.2.2. Healthcare Payers
7.2.3. Healthcare Providers
7.2.4. Other End Users
Chapter 8. RWE Oncology Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global RWE Oncology Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.2.3. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.3. Europe
8.3.1. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.3.3. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.4.3. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.5. Latin America
8.5.1. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.5.3. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.6.3. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. IQVIA Holdings Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Component/Service
9.2.1.3. Financial PerApplicationance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Veracyte, Inc.
9.2.3. Flatiron Health, Inc.
9.2.4. IBM Corporation
9.2.5. Oracle Corporation
9.2.6. SAS Institute Inc.
9.2.7. ICON plc
9.2.8. Parexel International Corporation
9.2.9. Syneos Health, Inc.
9.2.10. Cognizant Technology Solutions Corporation
9.2.11. UnitedHealth Group Incorporated
9.2.12. Anthem, Inc.
9.2.13. Clinigen Group plc
9.2.14. PerkinElmer, Inc.
9.2.15. Tempus Labs, Inc.
9.2.16. Other Players
Segmentation of Real World Evidence (RWE) Oncology Market-
Real World Evidence (RWE) Oncology Market By Component-
Real World Evidence (RWE) Oncology Market By Application-
Real World Evidence (RWE) Oncology Market By End-User-
Real World Evidence (RWE) Oncology Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
